Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Saved in:
| Title: | Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). |
|---|---|
| Authors: | Strober B; Department of Dermatology, Yale University, New Haven, Connecticut, USA.; Central Connecticut Dermatology Research, Cromwell, Connecticut, USA., Blauvelt A; Oregon Medical Research Center, Portland, Oregon, USA., Warren RB; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.; Manchester NIHR Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Papp KA; Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Armstrong AW; Department of Dermatology, University of California Los Angeles, Los Angeles, California, USA., Gordon KB; Dermatology - Froedtert Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Morita A; Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Alexis AF; Department of Dermatology, Weill Cornell Medicine, New York, New York, USA., Lebwohl M; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Foley P; Skin Health Institute and Probity Medical Research, Melbourne, Victoria, Australia., Kisa RM; Bristol Myers Squibb, Princeton, New Jersey, USA., Colston E; Bristol Myers Squibb, Princeton, New Jersey, USA., Wang T; Bristol Myers Squibb, Princeton, New Jersey, USA., Banerjee S; Bristol Myers Squibb, Princeton, New Jersey, USA., Thaçi D; Institute and Comprehensive Centre for Inflammation Medicine, University of Luebeck, Luebeck, Germany. |
| Source: | Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Aug; Vol. 38 (8), pp. 1543-1554. Date of Electronic Publication: 2024 Mar 07. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1468-3083 |
|---|---|
| DOI: | 10.1111/jdv.19925 |
